Association between tumor necrosis factor alpha rs1800629 polymorphism and risk of cervical cancer.
OBJECTIVE
The objective of this study was to evaluate the influence of the TNF-α rs1800629 polymorphism on the risk of cervical cancer.


METHODS
A comprehensive search of EMBASE, PubMed, Wanfang database and China National Knowledge Infrastructure (CNKI) was conducted and the papers published were retrieved. The fixed effects or random effects model was appropriately used to calculate the odds ratio (OR) along with 95% confidence interval (CI).


RESULTS
Data from sixteen articles containing nineteen studies were summarized in this meta-analysis. In general, we observed a marginal association between the TNF-α rs1800629 polymorphism and cervical cancer risk under the AA + AG vs. GG comparison model (OR=1.17, 95% CI=1.00-1.38, P=0.019 for heterogeneity). Interestingly, significantly increased risk was observed in the allele model (A vs. G: OR=1.19, 95% CI=1.02-1.38, P=0.006 for heterogeneity). In the stratified analysis by ethnicity, we found significant results in Caucasians.


CONCLUSIONS
Our results reveal that the Caucasian population may be at increased risk of developing invasive cervical cancer associated with the TNF-α rs1800629 polymorphism.
Department of VIP Obstetrics and Gynecology, Weifang Maternal and Child Health Hospital Weifang 261011, Shandong, China.
Lanling
L
Wang
Department of Otolaryngology, Affiliated Hospital of Weifang Medical University Weifang 261011, Shandong, China.
Kunpeng
K
Ma
Department of Pediatrics, Weifang Maternal and Child Health Hospital Weifang 261011, Shandong, China.
Zhiyong
Z
Wang
Department of VIP Obstetrics and Gynecology, Weifang Maternal and Child Health Hospital Weifang 261011, Shandong, China.
Yingying
Y
Mou
Department of VIP Obstetrics and Gynecology, Weifang Maternal and Child Health Hospital Weifang 261011, Shandong, China.
Li
L
Ma
Department of Pathological Obstetrics, Weifang Maternal and Child Health Hospital Weifang 261011, Shandong, China.
Yong
Y
Guo
TNF-α; cervical cancer; rs1800629